No profile data available.
Oric Pharmaceuticals, Inc. (ORIC) is a healthcare company in the additional cancer treatment drugs industry, based in South San Francisco, United States, with about 111 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$129.47 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $1.24 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.
Oric Pharmaceuticals reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$1.24 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional cancer treatment drugs) include AnaptysBio, Inc. (ANAB), Tyra Biosciences, Inc. (TYRA), Replimune Group, Inc. (REPL), Bicara Therapeutics Inc. (BCAX).